Could Novo Nordisk's New Weight-Loss Pill Be Just What Its Stock Needs?

Core Insights - Novo Nordisk's U.S.-listed shares increased by 9% following FDA approval for an oral version of its injectable Wegovy weight-loss drug, which demonstrated an average weight loss of 16.6% in clinical trials. The launch is anticipated in January [1][4]. Group 1: Company Performance - The approval of the oral Wegovy is expected to enhance demand for Novo Nordisk's weight-loss treatments and improve stock enthusiasm, which has declined this year due to rising competition and pressure to reduce drug prices [2]. - Despite the recent gains, Novo Nordisk's shares have decreased by over one-third in 2025, influenced by concerns regarding competition and pricing pressures from the Trump administration [3]. Group 2: Competitive Landscape - The timing of the FDA's approval may provide Novo Nordisk with a competitive advantage over Eli Lilly, whose weight-loss pill is projected to receive approval in the first quarter of 2026 [2].